First Trust Advisors
IOVA icon

First Trust Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

First Trust Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-84,397
Closed -$281K – 2649
2025
Q1 		$281K Sell
84,397
-239,849
-74% -$1.24M ﹤0.01% 2384
2024
Q4 		$2.4M Buy
+324,246
New +$3.01M ﹤0.01% 1730

Other funds holding IOVA

MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

First Trust Advisors's IOVA Position: Q2 2025 in Review

First Trust Advisors sold out of Iovance Biotherapeutics (IOVA) in Q2 2025, closing a stake of 84,397 shares — an estimated $281K sold.

First Trust Advisors first reported a position in IOVA in Q4 2024 and held it in 2 quarters. The position peaked at $2.4M in Q4 2024. 255 funds tracked by Wall St. Rank hold IOVA as of Q2 2025.

  • First Trust Advisors reported no remaining Iovance Biotherapeutics position as of Q2 2025 after selling out during the quarter.
  • First Trust Advisors sold 84,397 Iovance Biotherapeutics shares in Q2 2025, an estimated $281K.
  • First Trust Advisors first reported a position in Iovance Biotherapeutics in Q4 2024 and held it in 2 quarters.
  • First Trust Advisors's Iovance Biotherapeutics position peaked at $2.4M in Q4 2024.
  • 255 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2025.

Based on First Trust Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.